Enhancement of the immune response to chronic myeloid leukaemia via controlled treatment scheduling

We study the differential equations describing the chronic myeloid leukaemia. We propose a novel drug scheduling method to enhance the T-cell mediated immune response. The control strategy relies on the understanding of the immune boosting mechanism. The feasibility of the strategy is illustrated via simulations.

[1]  Doron Levy,et al.  Post-transplantation dynamics of the immune response to chronic myelogenous leukemia. , 2005, Journal of theoretical biology.

[2]  Frédéric Mazenc,et al.  Stability of a Gleevec and immune model with delays , 2008, 2008 47th IEEE Conference on Decision and Control.

[3]  Doron Levy,et al.  Dynamics and Potential Impact of the Immune Response to Chronic Myelogenous Leukemia , 2008, PLoS Comput. Biol..

[4]  Alessandro Astolfi,et al.  Immune response’s enhancement via controlled drug scheduling , 2007, 2007 46th IEEE Conference on Decision and Control.

[5]  B. Adams,et al.  HIV dynamics: Modeling, data analysis, and optimal treatment protocols , 2005 .

[6]  P. Klenerman,et al.  Low level viral persistence after infection with LCMV: a quantitative insight through numerical bifurcation analysis. , 2001, Mathematical biosciences.

[7]  C. Craddock,et al.  Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation. , 2002, Blood.

[8]  Martin A. Nowak,et al.  Dynamics of chronic myeloid leukaemia , 2005, Nature.

[9]  Holden T Maecker,et al.  Development and dynamics of robust T-cell responses to CML under imatinib treatment. , 2008, Blood.

[10]  Franziska Michor,et al.  Successful Therapy Must Eradicate Cancer Stem Cells , 2006, Stem cells.

[11]  Alessandro Astolfi,et al.  Activation of Immune Response in Disease Dynamics via Controlled Drug Scheduling , 2009, IEEE Transactions on Automation Science and Engineering.

[12]  Ryan Zurakowski,et al.  A model predictive control based scheduling method for HIV therapy. , 2006, Journal of theoretical biology.

[13]  Editors , 1986, Brain Research Bulletin.

[14]  PCR , 1989, Cell.

[15]  Silviu-Iulian Niculescu,et al.  ON STABILITY OF A COMBINED GLEEVEC AND IMMUNE MODEL IN CHRONIC LEUKEMIA: EXPLOITING DELAY SYSTEM STRUCTURE , 2007 .

[16]  F. Michor,et al.  Reply: The long-term response to imatinib treatment of CML , 2007, British Journal of Cancer.